Incidence and Prognosis of Brain Metastases in Head and Neck Cancer Patients at Diagnosis
| Autor: | Y.J. Rao, Arjun S. Joshi, Ian Messing, Martin Ojong-Ntui, Punam Thakkar, Sharad Goyal, Robert S. Siegel, Joseph F. Goodman, Jonathan H. Sherman |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Databases Factual medicine.medical_treatment 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Lymph node Aged Aged 80 and over Univariate analysis Chemotherapy business.industry Brain Neoplasms Incidence (epidemiology) Incidence Head and neck cancer Cancer Middle Aged medicine.disease Prognosis Survival Analysis United States Parotid gland Radiation therapy medicine.anatomical_structure Otorhinolaryngology Head and Neck Neoplasms 030220 oncology & carcinogenesis Female business 030217 neurology & neurosurgery |
| Zdroj: | The LaryngoscopeBIBLIOGRAPHY. 131(9) |
| ISSN: | 1531-4995 |
| Popis: | OBJECTIVES Limited data is available on head and neck cancer (HNC) patients presenting with brain metastases (BM) at initial diagnosis. We sought to evaluate the incidence, management, and treatment outcomes of these patients using the National Cancer Database (NCDB). METHODS We identified 465,925 patients diagnosed with HNC between 2010 and 2015 in the NCDB. 14,583 of these patients presented with metastatic disease to any site. 440 of these patients had BM at the time of initial diagnosis. Overall survival was compared using the Kaplan-Meier method. Cox proportional hazard modeling, propensity score matching, and subgroup analyses were performed. RESULTS The median age overall was 62.0 years. Nasopharynx NOS (13.2%) and Parotid Gland (10.9%) were the most common anatomical sites with the highest frequency of BM. The overall median survival time was 7.1 months. Predictors for the presence of BM included distant metastasis to the bone, liver, or lung on univariate analysis, and bone or lung on multivariate analysis. High-risk Human Papilloma Virus status was associated with a lower chance of BM. No pattern was determined when comparing lymph node level involvement and BM. The median survival for patients receiving radiation therapy and multi-agent chemotherapy was 8.4 and 11.7 months, respectively. Immunotherapy administered as first course therapy did not influence median survival. Most patients received radiation (62.7%) therapy and chemotherapy (50.2%). CONCLUSIONS The data extracted and analyzed from the NCDB should work to aid in the surveillance and management of BM in patients with HNC. LEVEL OF EVIDENCE 4 Laryngoscope, 131:E2543-E2552, 2021. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text